HCC
Clinical trials for HCC explained in plain language.
Never miss a new study
Get alerted when new HCC trials appear
Sign up with your email to follow new studies for HCC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hepatitis b liver cancer patients: immunotherapy trial launches
Disease control OngoingThis study tests the drug pembrolizumab in 30 people with advanced liver cancer caused by hepatitis B. The goal is to see if the drug can shrink tumors and improve survival, while also studying how the immune system changes during treatment. Participants must have stable hepatiti…
Matched conditions: HCC
Phase: PHASE2 • Sponsor: CCTU • Aim: Disease control
Last updated May 17, 2026 05:34 UTC
-
Can cabozantinib rescue liver cancer patients after immunotherapy fails?
Disease control OngoingThis study tests the drug cabozantinib in 20 people with advanced liver cancer (HCC) whose disease got worse after immunotherapy. The goal is to see if cabozantinib can slow tumor growth and improve survival. Participants take a daily pill, and researchers track side effects and …
Matched conditions: HCC
Phase: PHASE2 • Sponsor: Stephen Chan Lam • Aim: Disease control
Last updated May 17, 2026 05:27 UTC
-
Engineered immune cells take on Hard-to-Treat liver cancer in early trial
Disease control OngoingThis early-phase study tests a new treatment for people with advanced liver cancer that has not responded to standard therapies. The treatment uses specially engineered immune cells (CAR-T cells) designed to target a protein called IL1RAP on cancer cells. Only 3 participants are …
Matched conditions: HCC
Phase: PHASE1 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Custom-Made DNA vaccine takes on advanced liver cancer
Disease control OngoingThis study tests a personalized DNA vaccine (made from a patient's own tumor mutations) combined with an immune booster and the drug pembrolizumab in 36 adults with advanced liver cancer (HCC). The goal is to see if the vaccine is safe and can activate the immune system to fight …
Matched conditions: HCC
Phase: PHASE1, PHASE2 • Sponsor: Geneos Therapeutics • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New hope for advanced liver cancer: experimental drug faces off against standard therapy
Disease control OngoingThis study tests a new drug called pracytarabine against the standard drug regorafenib in people with advanced liver cancer that has not responded to targeted therapy and immunotherapy. About 60 adults aged 18-75 will take part. The main goal is to see how many patients live at l…
Matched conditions: HCC
Phase: PHASE2, PHASE3 • Sponsor: Xi'an Xintong Pharmaceutical Research Co.,Ltd. • Aim: Disease control
Last updated May 07, 2026 18:43 UTC